Analysis
What the administration claimed
The FDA approved Orzeyful (oveporexton) as the first medicine approved in the United States to treat narcolepsy type 1 as a complete disorder addressing the full range of its symptoms and the first to directly target loss of orexin signaling.
Claimant: U.S. Food and Drug Administration Agency (press release)
Agency or office: U.S. Food and Drug Administration
Context
FDA press release announcing approval of Orzeyful (oveporexton) tablets for treatment of narcolepsy type 1 in adults (Aug 5, 2026).
Evidence
The claim comes directly from the FDA's Aug 5, 2026 press release announcing approval. The press release states both that Orzeyful is approved to treat narcolepsy type 1 as a complete disorder and that it is the first approved therapy to act by restoring orexin signaling. Verifying the 'first' element requires checking prior FDA approvals and the mechanisms of previously approved narcolepsy therapies; the FDA press release itself presents this as the agency's determination at the time of approval.